Product Information
60275-1-Ig targets Podoplanin in WB, IHC, ELISA applications and shows reactivity with human, rat samples.
| Tested Reactivity | human, rat |
| Cited Reactivity | human |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag2201 Product name: Recombinant human PDPN,D2-40,M2A protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-238 aa of BC022812 Sequence: MLTPLGKFSTAKFAVRLPRVWEARAPSLSGAPAPTPPAPPPSRSSRLGLWPRCFLIFPQLRILLLGPQESNNSTGTMWKVSALLFVLGSASLWVLAEGASTGQPEDDTETTGLEGGVAMPGAEDDVVTPGTSEDRYKSGLTTLVATSVNSVTGIRIEDLPTSESTVHAQEQSPSATASNVATSHSTEKVDGDTQTTVEKDGLSTVTLVGIIVGVLLAIGFIGGIIVVVMRKMSGRYSP Predict reactive species |
| Full Name | podoplanin |
| Calculated Molecular Weight | 17 kDa, 25 kDa |
| GenBank Accession Number | BC022812 |
| Gene Symbol | Podoplanin |
| Gene ID (NCBI) | 10630 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein G purification |
| UNIPROT ID | Q86YL7 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Publications
What published studies show
Anti-Podoplanin antibody (Cat# 60275-1-Ig) has 1 total citation. It appears in JTO Clinical Research Reports (IF 3.6), published in December 2024. The study investigates solid predominant histology and high Podoplanin expression in cancer-associated fibroblasts as predictors of primary resistance to osimertinib in EGFR-mutated lung adenocarcinoma, using the antibody for IHC on human tissue. The associated research field is thoracic oncology / lung cancer biomarker research.
| Species | Application | Title |
|---|---|---|
JTO Clin Res Rep Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma |
